Form 4: Apellis Pharmaceuticals Grants Significant Stock Option Award to Chief Business & Strategic Officer

Apellis Pharmaceuticals, Inc. has granted 82,500 stock options to its Chief Business & Strategic Officer, Mark DeLong, at an exercise price of $19.39, with a two-year vesting schedule.

Summary

• Mark Jeffrey DeLong, Chief Business & Strategic Officer of Apellis Pharmaceuticals, Inc. (APLS), was granted 82,500 stock options.
• The transaction date for this grant was June 9, 2025.
• The exercise price for these stock options is $19.39 per share.
• The options will vest over a two-year period, with 50% vesting on the one-year anniversary and the remaining 50% on the two-year anniversary of the grant date, contingent upon continued service.
• The expiration date for these stock options is June 9, 2035.
• Following this transaction, Mark DeLong beneficially owns 82,500 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is a routine and positive event, as it aligns management's interests with long-term shareholder value and incentivizes continued commitment to the company's performance. It does not indicate any immediate operational or financial changes, but rather a standard compensation practice.

Positives

• The grant of stock options aligns the Chief Business & Strategic Officer's financial interests with the long-term performance and shareholder value of Apellis Pharmaceuticals.
• This compensation structure incentivizes the executive to contribute to the company's sustained growth and success over the vesting period.

Future Outlook

The stock option grant with a two-year vesting schedule indicates a forward-looking incentive for the Chief Business & Strategic Officer, tying a portion of his compensation to the company's future performance and his continued service.

Industry Context

The granting of stock options is a common and standard practice for executive compensation within the biotechnology and pharmaceutical industries, designed to attract, retain, and motivate key talent by aligning their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: Benefit from the alignment of executive incentives with long-term company performance.
• Employees: May view this as a positive sign of executive commitment and stability within the company.

Next Steps

• Continued service by Mark DeLong to meet the vesting conditions for the stock options.
• Future vesting events on the one-year and two-year anniversaries of the grant date.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Mark DeLong, Stock Option Grant, Executive Compensation, Insider Transaction, SEC Form 4, Equity Award, Pharmaceuticals